pamidronate has been researched along with Bone Diseases, Metabolic in 47 studies
Bone Diseases, Metabolic: Diseases that affect the METABOLIC PROCESSES of BONE TISSUE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to test the efficacy of low doses of pamidronate in increasing bone mineral density (BMD) in non-ambulatory children and adolescents with cerebral palsy (CP)." | 9.12 | Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study. ( Bruzoni, M; Coughlin, S; Heldt, K; Kreikemeier, R; Lerner, G; Plotkin, H, 2006) |
| "Intravenous pamidronate increases axial BMD in adults with cystic fibrosis, but the high incidence of bone pain associated with this treatment might limit its use." | 9.09 | Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis. ( Adams, JE; Haworth, CS; Horrocks, AW; Mawer, EB; Selby, PL; Webb, AK, 2001) |
| "To investigate if intravenous pamidronate improves bone density in a cohort of patients with chronic neurological conditions and low bone density, in whom fractures and bone pain are impacting on care." | 7.76 | Pamidronate improves pain, wellbeing, fracture rate and bone density in 14 children and adolescents with chronic neurological conditions. ( Davis, E; Howe, W; Valentine, J, 2010) |
| "All patients had osteopenia, diminished osteoid formation and bone volume on histomorphometry pre-therapy with high turnover bone disease (HTO) in TM and low-turnover disease (LTO) in TI." | 6.77 | Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome. ( Bajoria, R; Byers, M; Chatterjee, R; Davis, BA; Porter, JB; Pringle, J; Shah, FT; Sooranna, D, 2012) |
| "The aim of this study was to test the efficacy of low doses of pamidronate in increasing bone mineral density (BMD) in non-ambulatory children and adolescents with cerebral palsy (CP)." | 5.12 | Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study. ( Bruzoni, M; Coughlin, S; Heldt, K; Kreikemeier, R; Lerner, G; Plotkin, H, 2006) |
| "To evaluate in a double-blind, placebo-controlled clinical trial the safety and efficacy of intravenous pamidronate to treat osteopenia in nonambulatory children with cerebral palsy." | 5.10 | Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. ( Bachrach, SJ; Harcke, HT; Henderson, RC; Kecskemethy, HH; Lark, RK; Miller, F, 2002) |
| "Intravenous pamidronate increases axial BMD in adults with cystic fibrosis, but the high incidence of bone pain associated with this treatment might limit its use." | 5.09 | Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis. ( Adams, JE; Haworth, CS; Horrocks, AW; Mawer, EB; Selby, PL; Webb, AK, 2001) |
| "To investigate if intravenous pamidronate improves bone density in a cohort of patients with chronic neurological conditions and low bone density, in whom fractures and bone pain are impacting on care." | 3.76 | Pamidronate improves pain, wellbeing, fracture rate and bone density in 14 children and adolescents with chronic neurological conditions. ( Davis, E; Howe, W; Valentine, J, 2010) |
| "In recent years, bisphosphonates, primarily intravenous (iv) pamidronate, have become very widely used in children with severe osteogenesis imperfecta (OI)." | 3.73 | Low doses of pamidronate for the treatment of osteopenia in non-ambulatory children. ( Henderson, R, 2006) |
| " Bone densitometry is particularly effective for early detection of patients at risk for fracture and is of practical interest since patients with osteoporosis can now be treated with Pamidronate." | 3.71 | [Bone evaluation in ten adults with cutaneous mastocytosis]. ( Armingaud, P; Benhamou, CL; Estève, E; Kerdraon, R; Lespessailles, E; Petavy-Catala, C; Zerkak, D, 2002) |
| "The successful use of pamidronate, a bisphosphonate, for the treatment of hypercalcemia and/or osteopenia is reported in three children with renal failure or following renal transplant." | 3.70 | The use of pamidronate in three children with renal disease. ( Rodd, C; Sellers, E; Sharma, A, 1998) |
| "All patients had osteopenia, diminished osteoid formation and bone volume on histomorphometry pre-therapy with high turnover bone disease (HTO) in TM and low-turnover disease (LTO) in TI." | 2.77 | Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome. ( Bajoria, R; Byers, M; Chatterjee, R; Davis, BA; Porter, JB; Pringle, J; Shah, FT; Sooranna, D, 2012) |
| "Pamidronate was comparable to alendronate in prevention of early bone loss after kidney transplantation." | 2.76 | Comparison of alendronate and pamidronate on bone loss in kidney transplant patients for the first 6 months of transplantation. ( Alasti, M; Beladi Mousavi, SS; Ghorbani, A; Omidvar, B; Shahbazian, H; Shariat Nabavi, SJ, 2011) |
| "In contrast, inhibition of bone resorption by pamidronate could preserve bone mineral and reduce the risk of renal stone formation during prolonged bed rest." | 2.71 | Intravenous pamidronate prevents femoral bone loss and renal stone formation during 90-day bed rest. ( Felsenberg, D; Fukunaga, M; Kohri, K; Matsumoto, T; Mizuno, K; Nakamura, T; Ohshima, H; Rittweger, J; Sekiguchi, C; Watanabe, Y, 2004) |
| "Very rapid bone loss, osteopenia and skeletal morbidity after renal transplantation have been well documented and found to occur in a sex dependent fashion." | 2.69 | Pamidronate therapy as prevention of bone loss following renal transplantation. ( Almond, MK; Ball, E; Cunningham, J; Evans, K; Fan, SL, 2000) |
| "Hypercalcemia has been described as a possible complication of many pediatric malignancies." | 2.45 | Hypercalcemia in pediatric acute megakaryocytic leukemia: case report and review of the literature. ( Ahmed, I; Cushing, B; Qayed, M; Rajpurkar, M; Valentini, RP, 2009) |
| " Pre-treatment with the bisphosphonate pamidronate started at 4 weeks of age over a period of 2 weeks or 6 weeks (cumulative dose 8 mg/kg for both) to assess the effectiveness of the two dosing regimens in ameliorating glucocorticoid-induced bone loss." | 1.51 | Pre-treatment with Pamidronate Improves Bone Mechanical Properties in Mdx Mice Treated with Glucocorticoids. ( Chen, J; Grynpas, MD; Mitchell, J; Yoon, SH, 2019) |
| "The inhibition of bone resorption by pamidronate in osteopenic mice alleviates the histological OA score with a reduction in the expression of aggrecanases." | 1.38 | Targeting bone alleviates osteoarthritis in osteopenic mice and modulates cartilage catabolism. ( Ah Kioon, MD; Cohen-Solal, ME; de Vernejoul, MC; Funck-Brentano, T; Hannouche, D; Hay, E; Lin, H; Lioté, F; Nizard, R; Orcel, P; Schiltz, C, 2012) |
| " Adverse events were measured by collecting calcium levels before and after infusions." | 1.38 | Evaluation and comparison of safety, convenience and cost of administering intravenous pamidronate infusions to children in the home and ambulatory care settings. ( DeHaai, K; Kreikemeier, RM; Lutz, RE; Rush, ET, 2012) |
| "pamidronate was given for 6 months." | 1.31 | [Fibrous dysplasia: differential diagnosis from Paget's disease]. ( Heilmann, P; Kasperk, Ch; Nawroth, P; Schulz, A; Wagner, P, 2002) |
| "Pamidronate treatment seemed to increase trabecular bone density, although it was not effective in maintaining the AWcc of the operated extremity." | 1.31 | Pamidronate increases trabecular bone mineral density in immobilization osteopenia in male rats. ( Alhava, E; Arnala, I; Huuskonen, J; Olkkonen, H, 2001) |
| "In a model of preestablished osteopenia, caused by estrogen deprivation, OLPA stopped the progression of the bone mass loss (0." | 1.30 | [Experimental effects of olpadronate and pamidronate on bone mass]. ( Mondelo, N; Montuori, E; Parma, MD; Peluffo, VA; Piccinni, E; Zanchetta, JR, 1997) |
| "6 mg/kg of MDL 103,323 did not further increase BMD or bone strength, indicating a bell-shaped dose-response curve." | 1.30 | The new selective estrogen receptor modulator MDL 103,323 increases bone mineral density and bone strength in adult ovariectomized rats. ( Ammann, P; Bonjour, JP; Bourrin, S; Brunner, F; Meyer, JM; Rizzoli, R, 1999) |
| "Immobilization in this model induces osteopenia and increases turnover in cancellous bone." | 1.29 | The effect of pamidronate in a new model of immobilization in the dog. ( Grynpas, MD; Kasra, M; Pritzker, KP; Renlund, R, 1995) |
| "No hypocalcemia was detected." | 1.29 | [Effect of low doses of oral pamidronate (APD) on the calcemia of osteopenic or osteoporotic patients]. ( Castelli, G; Kerzberg, EM; Lloret, AP; Roldan, EJ, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.13) | 18.7374 |
| 1990's | 11 (23.40) | 18.2507 |
| 2000's | 21 (44.68) | 29.6817 |
| 2010's | 14 (29.79) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, N | 1 |
| Reilly, RF | 1 |
| Spirlandeli, AL | 1 |
| Dick-de-Paula, I | 1 |
| Zamarioli, A | 1 |
| Jorgetti, V | 1 |
| Ramalho, LNZ | 1 |
| Nogueira-Barbosa, MH | 1 |
| Volpon, JB | 1 |
| Jordão, AA | 1 |
| Cunha, FQ | 1 |
| Fukada, SY | 1 |
| de Paula, FJA | 1 |
| Chen, J | 1 |
| Yoon, SH | 1 |
| Grynpas, MD | 2 |
| Mitchell, J | 1 |
| Pirbhai, A | 1 |
| Rajak, SN | 1 |
| Goold, LA | 1 |
| Cunneen, TS | 1 |
| Wilcsek, G | 1 |
| Martin, P | 1 |
| Leibovitch, I | 1 |
| Selva, D | 1 |
| Veszelyné Kotán, E | 1 |
| Mészaros, Á | 1 |
| Qayed, M | 1 |
| Ahmed, I | 1 |
| Valentini, RP | 1 |
| Cushing, B | 1 |
| Rajpurkar, M | 1 |
| Dayer, R | 1 |
| Brennan, TC | 1 |
| Rizzoli, R | 2 |
| Ammann, P | 2 |
| Chatterjee, R | 2 |
| Bajoria, R | 2 |
| Howe, W | 1 |
| Davis, E | 1 |
| Valentine, J | 1 |
| Torregrosa, JV | 1 |
| Fuster, D | 1 |
| Monegal, A | 1 |
| Gentil, MA | 1 |
| Bravo, J | 1 |
| Guirado, L | 1 |
| Muxí, A | 1 |
| Cubero, J | 1 |
| Arundel, P | 1 |
| Offiah, A | 1 |
| Bishop, NJ | 1 |
| Bartl, R | 1 |
| Omidvar, B | 1 |
| Ghorbani, A | 1 |
| Shahbazian, H | 1 |
| Beladi Mousavi, SS | 1 |
| Shariat Nabavi, SJ | 1 |
| Alasti, M | 1 |
| Funck-Brentano, T | 1 |
| Lin, H | 1 |
| Hay, E | 1 |
| Ah Kioon, MD | 1 |
| Schiltz, C | 1 |
| Hannouche, D | 1 |
| Nizard, R | 1 |
| Lioté, F | 1 |
| Orcel, P | 1 |
| de Vernejoul, MC | 1 |
| Cohen-Solal, ME | 1 |
| Rush, ET | 1 |
| DeHaai, K | 1 |
| Kreikemeier, RM | 1 |
| Lutz, RE | 1 |
| Shah, FT | 1 |
| Davis, BA | 1 |
| Byers, M | 1 |
| Sooranna, D | 1 |
| Pringle, J | 1 |
| Porter, JB | 1 |
| Younes, H | 1 |
| Farhat, G | 1 |
| el-Hajj Fuleihan, G | 1 |
| Barr, RD | 1 |
| Guo, CY | 1 |
| Wiernikowski, J | 1 |
| Webber, C | 1 |
| Wright, M | 1 |
| Atkinson, S | 1 |
| Wagner, P | 1 |
| Heilmann, P | 1 |
| Schulz, A | 1 |
| Nawroth, P | 1 |
| Kasperk, Ch | 1 |
| Henderson, RC | 1 |
| Lark, RK | 1 |
| Kecskemethy, HH | 1 |
| Miller, F | 1 |
| Harcke, HT | 2 |
| Bachrach, SJ | 1 |
| Lee, CT | 1 |
| Huynh, VM | 1 |
| Lai, LW | 1 |
| Lien, YH | 1 |
| Grissom, LE | 1 |
| Montangero, VE | 1 |
| Capiglioni, R | 1 |
| Roldán, EJ | 2 |
| Watanabe, Y | 1 |
| Ohshima, H | 1 |
| Mizuno, K | 1 |
| Sekiguchi, C | 1 |
| Fukunaga, M | 1 |
| Kohri, K | 1 |
| Rittweger, J | 1 |
| Felsenberg, D | 1 |
| Matsumoto, T | 1 |
| Nakamura, T | 1 |
| Bin-Abbas, BS | 1 |
| Al-Ashwal, AA | 1 |
| Al-Zayed, ZS | 1 |
| Sakati, NA | 1 |
| Tokumoto, T | 1 |
| Tanabe, K | 1 |
| Toma, H | 1 |
| Akiba, T | 1 |
| Lipton, A | 1 |
| Nasr, SH | 1 |
| Preddie, DC | 1 |
| Markowitz, GS | 1 |
| Appel, GB | 1 |
| D'Agati, VD | 1 |
| Henderson, R | 1 |
| Plotkin, H | 1 |
| Coughlin, S | 1 |
| Kreikemeier, R | 1 |
| Heldt, K | 1 |
| Bruzoni, M | 1 |
| Lerner, G | 1 |
| Cheng, PT | 1 |
| Chan, C | 1 |
| Müller, K | 1 |
| Nimni, ME | 1 |
| Garnero, P | 1 |
| Grimaux, M | 1 |
| Seguin, P | 1 |
| Delmas, PD | 1 |
| Abe, T | 1 |
| Chow, JW | 1 |
| Lean, JM | 1 |
| Chambers, TJ | 1 |
| Ferretti, JL | 1 |
| Delgado, CJ | 1 |
| Capozza, RF | 1 |
| Cointry, G | 1 |
| Montuori, E | 2 |
| Roldán, E | 1 |
| Pérez Lloret, A | 1 |
| Zanchetta, JR | 2 |
| Kanis, JA | 1 |
| Kasra, M | 1 |
| Renlund, R | 1 |
| Pritzker, KP | 1 |
| Kerzberg, EM | 1 |
| Castelli, G | 1 |
| Lloret, AP | 1 |
| Mondelo, N | 1 |
| Parma, MD | 1 |
| Peluffo, VA | 1 |
| Piccinni, E | 1 |
| Sellers, E | 1 |
| Sharma, A | 1 |
| Rodd, C | 1 |
| Bourrin, S | 1 |
| Bonjour, JP | 1 |
| Brunner, F | 1 |
| Meyer, JM | 1 |
| Fan, SL | 1 |
| Almond, MK | 1 |
| Ball, E | 1 |
| Evans, K | 1 |
| Cunningham, J | 1 |
| Haworth, CS | 1 |
| Selby, PL | 1 |
| Adams, JE | 1 |
| Mawer, EB | 1 |
| Horrocks, AW | 1 |
| Webb, AK | 1 |
| Huuskonen, J | 1 |
| Arnala, I | 1 |
| Olkkonen, H | 1 |
| Alhava, E | 1 |
| Zeni, S | 1 |
| Gomez-Acotto, C | 1 |
| Mautalen, C | 1 |
| Armingaud, P | 1 |
| Zerkak, D | 1 |
| Lespessailles, E | 1 |
| Petavy-Catala, C | 1 |
| Kerdraon, R | 1 |
| Benhamou, CL | 1 |
| Estève, E | 1 |
| Tan, PL | 1 |
| Katz, JM | 1 |
| Ames, R | 1 |
| Caughey, DE | 1 |
| Gray, HD | 1 |
| Ibbertson, HK | 1 |
| Watson, JD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation[NCT02074631] | Phase 2 | 80 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| Simulation of a Mission Aboard the International Space Station by a Long Duration Anti-Orthostatic Bed Confinement at - 6° (90 Days) on Healthy Subjects:1/Perfecting of Preventive Methods (Muscular Exercise and Biphosphonates) and Evaluation of the Effect[NCT00311571] | Phase 1 | 28 participants | Interventional | 2001-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for pamidronate and Bone Diseases, Metabolic
| Article | Year |
|---|---|
Hungry bone syndrome.
Topics: Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitriol; Calcium; Diphosphonates; Hum | 2017 |
Bisphosphonate-Induced Orbital Inflammation: A Case Series and Review.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Di | 2015 |
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I].
Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic A | 2016 |
Hypercalcemia in pediatric acute megakaryocytic leukemia: case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Diseases, Met | 2009 |
[Treatment of bone disease in chronic kidney disease and in renal transplant recipients under K/DOQI clinical practice guidelines].
Topics: Bone Density; Bone Diseases, Metabolic; Calcitonin; Chronic Disease; Diphosphonates; Epoxy Compounds | 2004 |
New therapeutic agents for the treatment of bone diseases.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Bone Diseases, Metabolic; Bo | 2005 |
Bone and cancer: pathophysiology and treatment of metastases.
Topics: Analgesics, Non-Narcotic; Bone and Bones; Bone Diseases, Metabolic; Bone Neoplasms; Breast Neoplasms | 1995 |
9 trials available for pamidronate and Bone Diseases, Metabolic
| Article | Year |
|---|---|
Osteopenia-osteoporosis syndrome in patients with thalassemia: understanding of type of bone disease and response to treatment.
Topics: Absorptiometry, Photon; Anti-Inflammatory Agents; Bone Diseases, Metabolic; Diphosphonates; Female; | 2009 |
Efficacy of low doses of pamidronate in osteopenic patients administered in the early post-renal transplant.
Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeli | 2011 |
Comparison of alendronate and pamidronate on bone loss in kidney transplant patients for the first 6 months of transplantation.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Alendronate; Anti-Inflammatory Agents; Bone Den | 2011 |
Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome.
Topics: Adolescent; Adult; beta-Thalassemia; Biomarkers; Bone and Bones; Bone Density; Bone Diseases, Metabo | 2012 |
Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial.
Topics: Adolescent; Bone Diseases, Metabolic; Cerebral Palsy; Child; Diphosphonates; Double-Blind Method; Fe | 2002 |
Intravenous pamidronate prevents femoral bone loss and renal stone formation during 90-day bed rest.
Topics: Adult; Alkaline Phosphatase; Bed Rest; Biomarkers; Bone and Bones; Bone Density; Bone Diseases, Meta | 2004 |
Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study.
Topics: Adolescent; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Cerebral Palsy | 2006 |
Pamidronate therapy as prevention of bone loss following renal transplantation.
Topics: Absorptiometry, Photon; Adult; Aged; Alkaline Phosphatase; Aluminum; Anti-Inflammatory Agents; Bone | 2000 |
Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Bone Density; Bone Diseases, Metabolic; Calcium; Cystic | 2001 |
31 other studies available for pamidronate and Bone Diseases, Metabolic
| Article | Year |
|---|---|
Hepatic Osteodystrophy: The Mechanism of Bone Loss in Hepatocellular Disease and the Effects of Pamidronate Treatment.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling | 2017 |
Pre-treatment with Pamidronate Improves Bone Mechanical Properties in Mdx Mice Treated with Glucocorticoids.
Topics: Animals; Biomechanical Phenomena; Bone and Bones; Bone Diseases, Metabolic; Cancellous Bone; Cortica | 2019 |
PTH improves titanium implant fixation more than pamidronate or renutrition in osteopenic rats chronically fed a low protein diet.
Topics: Animal Nutritional Physiological Phenomena; Animals; Body Weight; Bone Density Conservation Agents; | 2010 |
Pamidronate improves pain, wellbeing, fracture rate and bone density in 14 children and adolescents with chronic neurological conditions.
Topics: Adolescent; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Child; Diphosp | 2010 |
Evolution of the radiographic appearance of the metaphyses over the first year of life in type V osteogenesis imperfecta: clues to pathogenesis.
Topics: Arm Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Cranial Fontanelles; Diphosph | 2011 |
[Inflammation of the jaws during treatment with bisphosphonates].
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseas | 2011 |
Targeting bone alleviates osteoarthritis in osteopenic mice and modulates cartilage catabolism.
Topics: ADAM Proteins; ADAMTS5 Protein; Animals; Bone and Bones; Bone Diseases, Metabolic; Bone Resorption; | 2012 |
Evaluation and comparison of safety, convenience and cost of administering intravenous pamidronate infusions to children in the home and ambulatory care settings.
Topics: Adolescent; Ambulatory Care; Bone Density Conservation Agents; Bone Diseases, Metabolic; Child; Cost | 2012 |
Efficacy and tolerability of cyclical intravenous pamidronate in patients with low bone mass.
Topics: Adult; Aged; Bone Density; Bone Diseases, Metabolic; Diphosphonates; Female; Humans; Injections, Int | 2002 |
Osteopenia in children with acute lymphoblastic leukemia: a pilot study of amelioration with Pamidronate.
Topics: Adolescent; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 2002 |
[Fibrous dysplasia: differential diagnosis from Paget's disease].
Topics: Absorptiometry, Photon; Adult; Anti-Inflammatory Agents; Biopsy; Bone Diseases, Metabolic; Diagnosis | 2002 |
Cyclosporine A-induced hypercalciuria in calbindin-D28k knockout and wild-type mice.
Topics: Animals; Anti-Inflammatory Agents; Bone Diseases, Metabolic; Calbindin 1; Calbindins; Calcium; Calci | 2002 |
Radiographic features of bisphosphonate therapy in pediatric patients.
Topics: Adolescent; Bone and Bones; Bone Density; Bone Development; Bone Diseases, Metabolic; Cerebral Palsy | 2003 |
Mandible and maxilla bone mineral density and threshold analysis studies by pQCT in two edentulous women receiving pamidronate.
Topics: Bone Demineralization, Pathologic; Bone Density; Bone Diseases, Metabolic; Bone Marrow; Calcificatio | 2003 |
Radiological features of bisphosphonate therapy in children with osteogenesis imperfecta.
Topics: Absorptiometry, Photon; Bone Density; Bone Diseases, Metabolic; Child; Child, Preschool; Diphosphona | 2004 |
Multiple myeloma, nephrotic syndrome and crystalloid inclusions in podocytes.
Topics: Acute Kidney Injury; Albumins; Bone Density Conservation Agents; Bone Diseases, Metabolic; Creatinin | 2006 |
Low doses of pamidronate for the treatment of osteopenia in non-ambulatory children.
Topics: Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Cerebral Palsy; Child; Chi | 2006 |
Cyclical treatment of osteopenic ovariectomized adult rats with PTH(1-34) and pamidronate.
Topics: Analysis of Variance; Animals; Bone and Bones; Bone Development; Bone Diseases, Metabolic; Diphospho | 1995 |
Biochemistry of bone induction and dystrophic calcification.
Topics: Acid Phosphatase; Alkaline Phosphatase; Animals; Bone Demineralization Technique; Bone Diseases, Met | 1994 |
Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro.
Topics: Adult; Antibodies, Monoclonal; Bone Diseases, Metabolic; Bone Neoplasms; Cell Line; Diphosphonates; | 1994 |
Estrogen does not restore bone lost after ovariectomy in the rat.
Topics: Animals; Body Weight; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Calcitonin; Diphospho | 1993 |
Protective effects of disodium etidronate and pamidronate against the biomechanical repercussion of betamethasone-induced osteopenia in growing rat femurs.
Topics: Animals; Betamethasone; Biomechanical Phenomena; Bone Diseases, Metabolic; Diphosphonates; Etidronic | 1993 |
The effect of pamidronate in a new model of immobilization in the dog.
Topics: Animals; Biomechanical Phenomena; Bone Density; Bone Diseases, Metabolic; Diphosphonates; Disease Mo | 1995 |
[Effect of low doses of oral pamidronate (APD) on the calcemia of osteopenic or osteoporotic patients].
Topics: Administration, Oral; Analysis of Variance; Bone Diseases, Metabolic; Bone Resorption; Calcium, Diet | 1996 |
[Experimental effects of olpadronate and pamidronate on bone mass].
Topics: Analysis of Variance; Animals; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Diphosphonate | 1997 |
The use of pamidronate in three children with renal disease.
Topics: Adolescent; Anti-Inflammatory Agents; Bone Density; Bone Diseases, Metabolic; Child; Diphosphonates; | 1998 |
The new selective estrogen receptor modulator MDL 103,323 increases bone mineral density and bone strength in adult ovariectomized rats.
Topics: Analysis of Variance; Animals; Biomechanical Phenomena; Bone Diseases, Metabolic; Bone Remodeling; C | 1999 |
Pamidronate increases trabecular bone mineral density in immobilization osteopenia in male rats.
Topics: Animals; Bone Density; Bone Diseases, Metabolic; Diphosphonates; Femur; Immobilization; Male; Pamidr | 2001 |
Do different aminobisphosphonates have similar preventive effect on experimental thyroid hormone-induced osteopenia in rats?
Topics: Alendronate; Animals; Body Weight; Bone Diseases, Metabolic; Diphosphonates; Female; Pamidronate; Ra | 2001 |
[Bone evaluation in ten adults with cutaneous mastocytosis].
Topics: Adult; Anti-Inflammatory Agents; Bone Density; Bone Diseases; Bone Diseases, Metabolic; Bone Marrow | 2002 |
Aminobisphosphonate inhibition of interleukin-1-induced bone resorption in mouse calvariae.
Topics: Animals; Bone Diseases, Metabolic; Cell Division; Diphosphonates; Interleukin-1; Mice; Pamidronate; | 1988 |